Metformin in Obese Children and Adolescents: The MOCA Trial
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Context: Childhood obesity is increasingly associated with type 2 diabetes (T2D). Metformin reduces the risk for T2D in adult obese nondiabetic patients, but the evidence in obese children and young people is inconclusive. Objective: The objective of the study was to assess the effect of metformin on body mass index sd score (BMI-SDS), metabolic risk factors, and adipokines. Design: This was a prospective, randomized, double-blind, placebo-controlled trial. Setting: The study was conducted at six pediatric endocrine centers in the United Kingdom. Participants: One hundred fifty-one obese children and young people with hyperinsulinemia and/or impaired fasting glucose or impaired glucose tolerance (metformin: 74, placebo: 77). The study was comprised of 67.5% females, 65.6% postpubertal individuals, and 23.8% British Asian or Afro-Caribbean participants. The age range was 8–18 yr, the mean age was 13.7 (sd 2.3) yr, and the mean BMI-SDS was +3.4 (sd 0.5). Interventions: The intervention included metformin 1 g in the morning and 500 mg in the evening vs. placebo for 6 months. Main Outcome Measure: The main outcome measure was a reduction in BMI-SDS at 6 months. Secondary outcomes included insulin and glucose levels from oral glucose tolerance tests, alanine aminotransferase (ALT), and adiponectin to leptin ratio (ALR) at 3 and 6 months. Results: Metformin was associated with a significant reduction in BMI-SDS compared with placebo at 6 months [mean difference −0.1 sd (95% confidence interval −0.18 to −0.02), P = 0.02]. Significant improvements at 3 months were found in the metformin group: fasting glucose, −0.16 mmol/liter (−0.31 to −0.00), P = 0.047; ALT, 19% (5–36%), P = 0.008; and ALR, 32% (4–67%), P = 0.02. Conclusions: Metformin therapy has a beneficial treatment effect over placebo for BMI-SDS, fasting glucose, ALT, and ALR ratio at 3 months, with changes in BMI-SDS sustained at 6 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Must, A., Jacques, P. F., Dallal, G. E., Bajema, C. J., & Dietz, W. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211053271904 · Cited by 2,233
Prevalence of impaired glucose tolerance among children and adolescents with marked obesity
Sinha, R., Fisch, G., Teague, B., Tamborlane, W. V., Banyas, B., Allen, K., Savoye, M., Rieger, V., Taksali, S., Barbetta, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012578 · Cited by 1,709
Type 2 diabetes among North adolescents: An epidemiologic health perspective
Fagot-Campagna, A., Pettitt, D. J., Engelgau, M. M., Burrows, N. R., Geiss, L. S., Valdez, R., Beckles, G. L. A., Saaddine, J., Gregg, E. W., Williamson, D. F., et al. (2000) · The Journal of Pediatrics · doi:10.1067/mpd.2000.105141 · Cited by 1,285
Insulin resistance in children: Consensus, perspective, and future directions
Levy-Marchal, C., Arslanian, S., Cutfield, W., Sinaiko, A., Druet, C., Marcovecchio, M. L., & Chiarelli, F. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1047 · Cited by 405
Yeckel, C. W., Weiss, R., Dziura, J., Taksali, S. E., Dufour, S., Burgert, T. S., Tamborlane, W. V., & Caprio, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031503 · Cited by 352
Effects of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant Children
Yanovski, J. A., Krakoff, J., Salaita, C. G., McDuffie, J. R., Kozlosky, M., Sebring, N. G., Reynolds, J. C., Brady, S. M., & Calis, K. A. (2011) · Diabetes · doi:10.2337/db10-1185 · Cited by 193
Cited by
Styne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2573 · Cited by 1,282
Hampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389
Kelly, A. S., Barlow, S. E., Rao, G., Inge, T. H., Hayman, L. L., Steinberger, J., Urbina, E. M., Ewing, L. J., & Daniels, S. R. (2013) · Circulation · doi:10.1161/cir.0b013e3182a5cfb3 · Cited by 980
“1 kg/m(2) (BMI reduction of ≈3%) over a treatment period of 6 months.(202) None of the other cardiometabolic risk factors measured in the study improved at 6 months.”
BackgroundChildhood obesity: increased risk for cardiometabolic disease and cancer in adulthood
Weihrauch-Blüher, S., Schwarz, P., & Klusmann, J.-H. (2019) · Metabolism · doi:10.1016/j.metabol.2018.12.001 · Cited by 566
O’Connor, E. A., Evans, C. V., Burda, B. U., Walsh, E. S., Eder, M., & Lozano, P. (2017) · JAMA · doi:10.1001/jama.2017.0332 · Cited by 500
Metadata
- Authors
- Kendall, D., Vail, A., Amin, R., Barrett, T., Dimitri, P., Ivison, F., Kibirige, M., Mathew, V., Matyka, K., McGovern, A., Stirling, H., Tetlow, L., Wales, J., Wright, N., Clayton, P., & Hall, C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-01-01
- Volume
- 98
- Issue
- 1
- Pages
- 322-329
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2119890307
- Cited by
- 119
- References
- 8
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.